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Most monoclonal antibodies (mAbs) generated from humans infected or vaccinated with
the 2009 pandemic H1N1 (pdmH1N1) inﬂuenza virus targeted the hemagglutinin (HA)
stem.These anti-HA stem mAbs mostly used IGHV1-69 and bound readily to epitopes on
the conventional seasonal inﬂuenza and pdmH1N1 vaccines.The anti-HA stem mAbs neu-
tralized pdmH1N1, seasonal inﬂuenza H1N1 and avian H5N1 inﬂuenza viruses by inhibiting
HA-mediated fusion of membranes and protected against and treated heterologous lethal
infections in mice with H5N1 inﬂuenza virus. This demonstrated that therapeutic mAbs
could be generated a few months after the new virus emerged. Human immunization with
the pdmH1N1 vaccine induced circulating antibodies that when passively transferred, pro-
tected mice from lethal, heterologous H5N1 inﬂuenza infections. We observed that the
dominant heterosubtypic antibody response against the HA stem correlated with the rela-
tive absence of memory B cells against the HA head of pdmH1N1, thus enabling the rare
heterosubtypic memory B cells induced by seasonal inﬂuenza and speciﬁc for conserved
sites on the HA stem to compete for T-cell help. These results support the notion that
broadly protective antibodies against inﬂuenza would be induced by successive vaccina-
tionwithconventionalinﬂuenzavaccinesbasedonsubtypesofHAinvirusesnotcirculating
in humans.
Keywords:pandemicH1N1inﬂuenza,vaccines,cross-protectiveantibodies,heterosubtypic,plasmablasts,memory
B cells, competition forT-cell help, hemagglutinin
INTRODUCTION
Each year seasonal inﬂuenza causes serious illnesses in 3–5 mil-
lion humans and 200,000–500,000 deaths (Chen and Subbarao,
2009).Protectionagainstinﬂuenzaisduetohigh-avidityantibod-
iesagainstthehemagglutinin(HA)protein,whichprotrudesfrom
theviralenvelopeandattachestheviriontothesialicacidreceptor
on the cells of the host (Wiley and Skehel, 1987). The hemagglu-
tinin protein has a globular head which mediates the attachment
of the virus to the host cells, and a stem, which mediates the
fusion of the viral membrane to the host cell membrane,enabling
the viral genome to enter the cells (Wiley and Skehel, 1987). If
antibodies against the head of the hemagglutinin are of sufﬁcient
afﬁnity/avidityandstericallyinhibitthereceptor-bindingsite,they
block attachment of the virus to the host cell (Knossow et al.,
2002). These protective antibodies are very speciﬁc for a given
isolate/subtype of inﬂuenza virus because the replication of the
inﬂuenza virus genome is error-prone. Thus inﬂuenza viruses are
rapidly selected with mutants of the HA that decrease the afﬁnity
of the protective antibodies so that they no longer block attach-
ment of the mutant virus. This variation in the inﬂuenza virus
is called “antigenic drift” and three dominant drifted inﬂuenza
viruses are incorporated into updated seasonal inﬂuenza vaccines
to induce protective antibodies to these variants.
Occasionally a more drastic change in the antigenicity of
the HA termed “antigenic shift” occurs. Consequently humans
have no protective antibodies against the “antigenically shifted”
inﬂuenza virus. If an antigen-shifted inﬂuenza virus transmits
readily between humans, it can cause an inﬂuenza pandemic.
The 1918 “Spanish” H1N1 inﬂuenza pandemic was probably
caused by an inﬂuenza virus that had come from avian species
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(Yen and Webster, 2009). The HA of the 1918 H1N1, 1957 H2N2,
1968 H3N2, and 2009 pandemic H1N1 inﬂuenza viruses ulti-
mately originated from avian inﬂuenza viruses (Yen and Webster,
2009). The 2009 pandemic inﬂuenza A H1N1 virus (pdmH1N1)
was generated by reassortment of the eight RNA molecules of
the inﬂuenza genome between two swine inﬂuenza viruses, both
with genes from avian,swine,and human inﬂuenza viruses (Ding
et al., 2009; Garten et al., 2009). In the HA of the 2009 pandemic
H1N1 inﬂuenza,21% of the amino-acids of the ectodomain were
non-identical with the corresponding residues in seasonal H1N1
virus and ∼50% in the key epitopes on the HA head were non-
identical (Xu et al., 2010). Infection of humans with inﬂuenza
virusesnotcirculatinginhumanscancauseserioushumanillness,
the highly pathogenic avian H5N1 inﬂuenza having a mortality
rate in humans of over 60% (Yen and Webster, 2009).
In contrast to the HA head, mutations in the HA stem are
not well-tolerated for viral infectivity because, after the virus
is endocytosed, the low pH in the endosome induces a com-
plex conformational change in the HA stem (Wiley and Skehel,
1987). This conformational change exposes a peptide that medi-
ates fusion of the viral and the endosomal membranes, enabling
the viral genome to access the cytoplasm. Antibodies against the
HA stem can block this conformational change and membrane
fusion (Okuno et al., 1993) and thus infectivity. Artiﬁcial phage-
display mAbs using the human immunoglobulin heavy (H) chain
and light (L) chain genes that were selected to bind the H5 HA
neutralize the infectivity of multiple subtypes of inﬂuenza viruses
by targeting a conserved site on the HA stem (Throsbyetal.,2008;
Sui et al.,2009). These mAbs preferentially used the H chain vari-
able region gene IGHV1-69. Crystallographic studies of two of
these artiﬁcial mAbs in complex with HA demonstrated that the
germline IGHV1-69 encodes key residues for a binding site for an
epitope on the stem of the HA (Ekiert et al.,2009;Sui et al.,2009).
The L chain did not contact the HA stem.
Techniques that enable copying of natural human monoclonal
antibodies (mAbs) binding to HA offers great advantages in dis-
secting the distribution of protective antibodies in terms of their
afﬁnity, epitope, cross-reactivity, heterosubtypic protection, V-
geneusage,clonotypicdominance,andnumbersof somaticmuta-
tions. Wrammert et al. (2008) generated copies of natural mAbs
from newly formed plasmablasts shortly after seasonal inﬂuenza
vaccination and found that none of the monoclonal antibod-
ies were heterosubtypic and all targeted the hemagglutinin head
(Wrammertetal.,2011).Likewise,memoryBcellsmakinghetero-
subtypicantibodiesagainsttheHAfromH5N1wereundetectable
in normal humans (Corti et al., 2010). However, after seasonal
inﬂuenza vaccination, heterosubtypic memory B cells (mainly
against the HA stem and using IGHV1-69) could be detected in
some individuals, although the frequency was variable and 26- to
200-fold less than that of memory B cells making antibodies spe-
ciﬁc for the seasonal inﬂuenza vaccine (Corti et al.,2010).A small
amount of heterosubtypic antibody in the serum was detected
but was insufﬁcient to neutralize the H5N1 inﬂuenza virus (Corti
et al., 2010), consistent with immunity against inﬂuenza being
very isolate-speciﬁc (Wiley and Skehel, 1987). As the gene used
for most heterosubtypic antibodies against the HA stem, IGHV1-
69, is present in most humans and the structural data indicated
that the H chain without the help of the L chain made the crit-
ical contacts with the HA stem by germline IGHV1-69 encoded
side-chains, these observations raised the question of why effec-
tive levels of cross-protective heterosubtypic antibodies are not
induced by infections or vaccinations with seasonal inﬂuenza
(Throsby et al.,2008; Sui et al., 2009).
Wrammert et al. (2011) reported that 5 of the 15 mAbs
against HA generated from three out of four people infected with
pdmH1N1 (Garten et al., 2009) were against the HA stem and
four used IGHV1-69. These ﬁve anti-HA stem mAbs neutralized
pdmH1N1 and seasonal H1N1 inﬂuenza viruses. We made more
extensive observations and have demonstrated that the anti-HA
stem mAbs induced by pdmH1N1 infection neutralized another
subtype of inﬂuenza A virus, the highly pathogenic avian H5N1
inﬂuenza. They also protected potently against and effectively
treated lethal infections in mice with H5N1. These published
observations (Wrammert et al., 2011) and our observations in
the winter of 2009–2010 suggested that infection with pdmH1N1
induces a high proportion of PB making heterosubtypic anti-
bodies and raised important questions. Would circulating lev-
els of heterosubtypic antibodies reach protective levels? Would
the pdmH1N1 vaccine similarly induce a protective heterosub-
typic antibody response? What was different about infection with
pdmH1N1 and why were there not a high frequency of anti-HA
stem mAbs induced by infection with seasonal inﬂuenza? Here we
provide answers to these questions.
RESULTS
Anti-HA STEM mAbs DOMINATE IN BOTH INFECTED AND VACCINATED
SUBJECTS
When the 2009 pandemic emerged, we set out to generate rapidly
therapeutic truly human monoclonal antibodies (mAbs) against
the HA (Mozdzanowska et al., 1997; Luke et al., 2006; Sim-
mons et al., 2007; Zhou et al., 2007; Hung et al., 2011) of the
pdmH1N1 virus (pdmHA). We used three approaches to gen-
erate human monoclonal antibodies (mAbs) that reacted with
HA of the pdmH1N1 virus. First, we randomly cloned antibodies
from newly generated plasmablasts (PB) circulating in the blood
of recentlyinfectedpatients.Thisapproachwasbaseduponobser-
vations that ∼7days after vaccination, PB that secrete antibodies
speciﬁc for the vaccine appear in the blood (Heilmann et al.,
1987; Barington et al., 1990) and form a signiﬁcant fraction of
the total PB (Odendahl et al., 2005; Wrammert et al., 2008). It
also exploited techniques that we had previously used to gen-
erate monoclonal antibodies from blood-borne PB by RT-PCR
and cloning and expression of the DNA encoding the antigen-
binding site from single PB (Babcook et al., 1996). In the absence
of data on the kinetics of entry of infection-speciﬁc PB into
the blood during infections, we collected blood from subjects
with laboratory-conﬁrmed pdmH1N1 infections ∼7days after
the onset of symptoms. We found many PB secreting antibod-
ies against pdmHA in the blood after infection (Figure 1). This
demonstrates that,during an infection,at least some newly gener-
ated PB enter the blood and do not all remain in lymphoid tissues
nearthesiteof infection,consistentwithdatapublishedafterward
with human infection with Respiratory SyncytialVirus (Lee et al.,
2010). We obtained our ﬁrst mAb (I4-128) against pdmHA in
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FIGURE 1 | Infection or vaccination with pdmH1N1 induces a dominant
antibody response that preferentially uses IGHV1-69 and that
cross-reacts with the HA of the highly pathogenic avian H5N1 inﬂuenza
virus. (A) Elispot assay showing spots of anti-pdmHA antibodies that had been
secreted by individual PB. (B) Pie chart representing all 48 mAbs fromTable 1.
The 95% conﬁdence intervals of IGHV1-69 usage were 38–66%. *8 of 9 mAbs
using IGHV4-39 were from a single subject, V2. (C,D) Cross-reactivity of
selected mAbs with the HA of inﬂuenza A/Hong Kong/156/197 (H5N1; Clade 0)
expressed by the A549 human cell-line. Binding was quantiﬁed by indirect
immunoﬂuorescence and the Cellomics instrument. (C) Cellomics images of
cells stained with either secondary antibodies alone or ﬁrst with mAb I4-128
(5μg/ml). (D) Percentage of cells stained with varying concentrations of the
indicated mAbs. Note that anti-stem HA mAbs that did not use IGHV1-69, like
V3-1E8 and I5-52 also bound to the H5 HA in this assay (data not shown). KE5,
an human anti-HCMV monoclonal antibody (McLean et al., 2005), was used as
a negative control with no signiﬁcant binding observed (data not shown).
August 2009, only months after the pdmH1N1 virus was identi-
ﬁed.ThemAbusedIGHV1-69 andboundreadilytotheHAof the
highly pathogenic avian inﬂuenzaA/Hong Kong/156/197 (H5N1)
virus (Figures 1C,D). As a second strategy we also puriﬁed PB
cellsthatboundﬂuorochrome-labeledpdmHAandusedRT-PCR
and cloning to generate additional mAbs from subjects infected
or vaccinated with pdmH1N1 (Table 1). We also used ﬂuorescent
cellsortingtopurifyindividualclass-switchedmemoryBcellsthat
boundtoﬂuorochrome-labeledpdmHA,expandedtheBcellsinto
clones and assayed the supernatants after a week for the presence
ofantibodiestopdmHAandusedRT-PCRandcloningtogenerate
mAbs against pdmHA.
In total, from ﬁve infected and three vaccinated subjects, we
generated 48 mAbs against pdmHA (Table 1). The sequences
of the 10 best-binding mAbs to pdmH1N1, 3 against the HA
head (V2-36, V2-7, and V4-17) and 7 against the HA stem (I4-
128, I5-24, I8-1B6, V3-1G10, V3-2C3, V3-2G6, and V3-3D2), are
listed in Table 2. Strikingly, 52% of the mAbs used the heavy-
chain immunoglobulin variable region gene IGHV1-69 (Table 1;
Figure 1B) which is used by only 3.6% of random B cells from
blood (De Wildt et al., 1999). The high frequency of usage of
IGHV1-69 in mAbs against pdmHA was seen whether the mAbs
were generated from subjects infected (44%) or vaccinated (57%)
with pdmH1N1, or from either PB (40%) or memory B cells
(65%).
A minority of mAbs (7 of 38 mAbs tested) inhibited hemag-
glutination by pdmH1N1 (Figure 2A) and most were of one
clonotype (Table 1) and bound to the HA head. We found like
others, that select mAbs using IGHV1-69 and other IGHV genes
bound to a site on the HA stem as judged by inhibition of the
binding of C179, a cross-protective anti-HA stem mAb (Okuno
et al.,1993;Figure2B).We noted,however,that this assay was not
speciﬁc for antibodies against the HA stem. Thus a mAb (V2-36)
that was clearly directed against the HA head because it inhib-
ited hemagglutination (Figure 2A), also inhibited binding of the
anti-HA stem mAb C179 (Figure 2B). However, we conﬁrmed
that many mAbs that inhibited the binding of C179 to pdmHA,
boundtotheHAstembyshowingthattheydidnotinhibithemag-
glutination by pdmH1N1 and that their binding was sensitive to
pre-treatment of HA at pH 5 (Figure 2C), which altered the con-
formation of the HA stem (Wiley and Skehel,1987;Throsby et al.,
2008). The binding by the anti-HA head mAb, V2-36 was not
affected by this treatment (Figure2C). By these three criteria,fail-
ure to inhibit hemagglutination by inﬂuenza virus, competitive
inhibition of C179 binding to HA, and inhibition of binding to
the mAb by pre-treatment of the HA at pH 5, another 6% of the
anti-pdmHA mAbs not using IGHV1-69 mapped to the HA stem
andprobablyboundtosubtlydifferentepitopes(e.g.,themAbI5-
52, which uses IGHV1-18 Figures 2A–C). We tested 20 out of 25
IGHV1-69-using mAbs for inhibition of hemagglutination with
pdmH1N1 and none proved positive at 20μg/ml. We tested 24 of
the IGHV1-69-using mAbs for binding to pdmHA treated at pH
5. We found that the binding of 20 of the mAbs was dramatically
reduced. Throsby et al. (2008),found a heterogeneity in the bind-
ing to low pH treated HA with different IGHV1-69-using mAbs.
However,we are still assessing the proportion of mAbs against the
www.frontiersin.org May 2012 | Volume 3 | Article 87 | 3Thomson et al. pdmH1N1 vaccination induces cross-protective antibodies
Table 1 |Truly human monoclonal antibodies binding to pdmHA.
mAb IGHV DJ κ/λ IGK/LV J IGHV mutations
(A) mAb GENERATED FROM PLASMABLASTS
I3-15 1-69*01 3-10 6 κ 1-39*01 2 18
I4-109# 3-33*01 4-17 4 λ 1-40*01 2 16
I4-112# 1-2*02 6-19 3 λ 2-8*01 2 5
I4-115# 3-20*01 3-10 4 κ 3-11*01 1 30
I4-128# 1-69*01 5-5 5 κ 1-5*03 2 13
I5-7 1-69*12 3-10 3 κ 3-15*01 1 29
I5-24 1-69*02 3-22 4 κ 3-20*01 2 29
I5-52 1-18*01 3-16 6 κ 2-30*01 1 11
I5-69 1-69*02 5-24 4 κ 3-11*01 5 8
V2-1 3-30*18 1-26 6 κ 3-20*01 1 15
V2-2Δ 4-39*01 6-13 5 λ 1-40*01 1 33
V2-3Δ 4-39*01 6-13 5 λ 1-40*01 1 33
V2-4Δ 4-39*01 6-13 5 λ 1-40*01 1 31
V2-7Δ 4-39*01 6-13 5 λ 1-40*01 1 21
V2-11Δ 4-39*01 6-13 5 λ 1-40*01 1 21
V2-36Δ 4-39*01 6-13 5 λ 1-40*01 1 33
V2-38Δ 4-39*01 6-13 5 λ 1-40*01 1 34
V2-12 4-39*03 3-22 4 κ 4-1*01 3 34
V4-1˚ 1-69*06 5-12 4 κ 3-20*01 2 29
V4-9 1-69*02 7-27 6 κ 3-15*01 1 34
V4-12 3-33*02 5-24 4 λ 3-1*01 3 31
V4-17* 4-39*01 3-3 4 λ 1-47*02 2 19
V4-18˚ 1-69*06 5-12 4 κ 3-20*01 2 23
V4-23 1-69*02 7-27 6 κ 1-39*01 1 34
V4-29 1-69*01 5-5 6 λ 2-14*01 2 28
(B) mAb GENERATED FROM MEMORY B CELLS
I4-1C4 1-69*09 4-23 5 κ 3-11*01 1 23
I4-1F7 3-66*01 1-26 2 κ 3-15*01 3 0
I4-1G8 2-70*11 2-8 6 λ 3-1*01 1 5
I8-1B6 1-69*01 3-3 6 λ 2-14*01 1 22
I14-1D9 1-69*04 2-15 4 κ 3-15*01 2 10
I14-1F8 5-51*01 5-12 6 κ 3-11*01 5 10
I14-2B6 4-59*01 2-8 3 κ 1-39*01 1 19
I14-2B7 1-18*01 2-8 6 κ 2-30*01 2 3
I14-2C5 3-30*03 6-6 4 κ 1-6*01 2 22
V3-1B9 3-11*01 3-3 3 κ 1-12*01 4 10
V3-1C6 1-69*01 1-1 6 λ 7-43*01 3 18
V3-1E8 3-33*01 1-26 4 λ 3-25*03 3 11
V3-1G10 1-69*06 1-14 5 κ 3-15*01 2 25
V3-2C2 1-69*06 3-9 4 κ 1-39*01 4 9
V3-2C3 1-69*01 3-10 5 κ 1-5*03 2 6
V3-2C10 1-69*01 5-12 5 κ 1-39*01 4 21
V3-2E2 1-69*01 3-10 4 κ 1-16*02 4 14
V3-2F10 1-69*06 3-22 4 κ 1-5*03 1 17
V3-2G6 1-69*01 3-16 4 κ 3-20*01 2 18
V3-3B3 1-69*01 3-10 3 λ 2-11*01 1 6
V3-3B6 1-69*06 2-2 6 κ 3-20*01 1 19
(Continued)
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Table 1 | Continued
mAb IGHV DJ κ/λ IGK/LV J IGHV mutations
V3-3C11 1-69*06 5-12 4 λ 2-14*01 1 9
V3-3D2 1-69*01 1-14 6 κ 1-16*-01 4 21
mAbs are named systematically, with the initial letter and number indicating the subject from which it had been generated, with I orV indicating that they were gen-
erated from a subject infected (I) or vaccinated (V) with the pdmH1N1 virus. All bound by ELISA to puriﬁed recombinant ectodomain of pdmHA and to the pdmH1N1
vaccine, and all but V4-17* also bound to the seasonal 2009/2010 vaccine and to H5 HA (A/Vietnam/1203/2004, Clade 1). mAbs in section (A) were generated from
PB, with
#indicating those generated from randomly chosen PB that were not sorted for their ability to bind pdmHA; other mAbs in section (A) were generated from
PB puriﬁed by their binding to pdmHA. mAbs in section (B) were generated from memory B cells puriﬁed by their binding to pdmHA.
Δ,◦Denote clonotypes.
HA stem. The most conclusive way to prove that they are against
the HA stem, is by making escape mutants, which has proven dif-
ﬁcult (Throsby et al., 2008; Sui et al., 2009; Wang et al., 2010).
As can be seen in Figure 2D, the anti-HA stem mAbs also com-
petedwithbiotinylatedI5-24(whichusedIGHV1-69)forbinding
to pdmHA. Of note, V2-36, which clearly was against the HA
head(Figure2A),competedwithbiotinylatedI5-24forbindingto
pdmHA(Figure2D).Moreover3outof 3IGHV1-69-usingmAbs
bound to the HA of highly pathogenic avian inﬂuenza A/Hong
Kong/156/197 (H5N1) virus (Figure 1D). Only two mAbs using
IGHV1-69 (from subject V4) were members of the same clono-
type. Notably,in the subject with the highest proportion of mAbs
using IGHV1-69, V3 (86%), all of the mAbs were from different
clonotypes.
Anti-HA STEM mAbs RECOGNIZED CROSS-REACTIVE EPITOPES ON
CONVENTIONAL SEASONAL AND pdmH1N1 VACCINES
With one exception, the anti-HA head mAb V4-17, all mAbs
including both anti-HA stem and head mAbs, bound to the
2009/2010 seasonal inﬂuenza vaccine and the pdmH1N1 vaccine
(Figure 3; Table 1) and all bound to the puriﬁed ectodomain of
H5 HA of an H5N1 avian inﬂuenza virus A/Vietnam 1203/2004
(Clade 1; Table 1; Figure 3). The binding of the anti-HA stem
mAbs to the seasonal inﬂuenza and pdmH1N1 vaccine was com-
parable to the binding of the anti-HA head mAbs (e.g., binding
of V2-36 to the seasonal inﬂuenza and pdmH1N1 vaccine and
binding of V4-17 to the pdmH1N1 vaccine, Figure 3). Thus, the
two conventionally manufactured vaccines were a good source of
the conserved epitopes on the HA stem and thus the failure of the
seasonal inﬂuenza vaccine to induce protective levels of hetero-
subtypic anti-HA stem antibodies (Wrammert et al., 2008; Corti
et al., 2010) was not due to the lack of the conserved epitopes in
the vaccine.
NEUTRALIZATION OF pdmH1N1 AND AVIAN H5N1 INFLUENZA VIRUS
INFECTIVITY BY anti-HA STEM ANTIBODIES
None of our anti-HA stem mAbs neutralized the pdmH1N1 or
current seasonal H1N1 inﬂuenza viruses in the standard WHO
microneutralization assay, performed in two experienced public
health laboratories. However,the minority of mAbs that inhibited
hemagglutination with the respective inﬂuenza virus, neutral-
ized. The WHO neutralization assay effectively detects antibodies
that block viral attachment, as the mixture of virus and anti-
body is incubated with the cells for only 3h and then washed
off. Subsequently the cells are cultured for 3–4days to allow the
inﬂuenza virus to replicate and produce a cytopathic effect.
We reasoned that, in the standard assay, the mixture of the
viruses and mAb will only be in contact with the host cells for
3h and, if the mAb targets the HA stem rather than the head, the
viruses will successfully attach to the host cells.After the virus and
the mAb are washed away, some of the mAb will dissociate from
viruses that are not endocytosed but still attached to the cells.
When the virus is ﬁnally endocytosed there may be insufﬁcient
mAb bound to the virus to inhibit membrane fusion. Thus the
virus will replicate and can infect other cells, unimpeded by the
m A ba si ti sn ol o n g e rp r e s e n t .
TheWHO assay was designed to detect neutralizing antibodies
in serum. The mixture of virus and sera was washed away after
3h incubation with the host cells because the human serum con-
tained trypsin inhibitors. The inclusion of trypsin in the assay
wasessentialbecauseenzymaticactionof trypsinwasnecessaryto
cleavethehemagglutininonthevirionsinordertoseeacytopathic
effect. This assay worked well with seasonal inﬂuenza where the
neutralizing antibodies were directed at the HA head and blocked
viral attachment. We modiﬁed the assay by leaving the virus and
mAbs in the cultures for the duration of the assay, mimicking
the constant presence of antibodies in an infection in vivo. With
thissimplemodiﬁcation,allof theanti-HAstemmAbstestedthen
completelyneutralizedpdmH1N1atconcentrationsrangingfrom
78 to 1250ng/ml (Figure 4A).
Anti-HAstemmAbsthatneutralizedpdmH1N1effectivelyalso
neutralized infectivity of the highly pathogenic avian inﬂuenza
virus A/Goose/Ger/R1400/07 (H5N1; Clade 2.2; Figures 4B,C).
Wedemonstratedthatthemechanismofneutralizationofinfectiv-
itywasinhibitionof H5HA-mediatedfusion(Throsbyetal.,2008;
Ekiertetal.,2009;Suietal.,2009;Figure4D).Theseanti-HAstem
mAbs had no neutralization activity against theA/Ck/Ger/R28/03
(H7N7) inﬂuenza virus (data not shown) consistent with the fail-
ure of most engineered mAbs using IGHV1-69 to bind to Group
2s u b t y p e so fH A( Throsby et al.,2008; Sui et al., 2009).
THERAPEUTIC EFFECTS OF mAbs AGAINST THE HEAD AND STEM OF
pdmH1N1 ON LETHAL IN VIVO INFECTIONS WITH A HUMAN ISOLATE
OF pdmH1N1
We then tested selected mAbs which we had generated against the
head and the stem of the pdmHA,for their therapeutic efﬁcacy in
mice with lethal infections of a human isolate of pdmH1N1. We
treated groups of ﬁve mice with each of six anti-HA stem mAbs
24h after lethal intranasal doses of a human isolate of pdmH1N1.
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Table 2 | Nucleotide sequences of the variable regions of 10 monoclonal neutralizing antibodies that had the highest avidity for pdmH1N1
hemagglutinin and that were studied in detail.
V2-36
pHC-2-36H:
ATGAAACATCTGTGGTTCTTCCTTCTGCTGGTGGCGGCTCCCAGATGGGTCCTGTCCGAGCTGCGGCTGCACGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGGGACCCTG
TCCCTCACGTGCACTGTGTCTGGTGGCTCCATCAGCGGAGGTAGTCATTACTGGGCCTGGATCCGCCAGTCCCCAGGGAAGGGCCTGGAGTGGATTGGAAGTATCTACTAT
AGTGGAAGCACCTACGACAGCCCGTCCCTCAAGAGTCGACTCAGCATGTCCGTGGACAAGTCGAAGAACCAGTTCCACCTGACGCTGAGGTCTGTGACCGCCGCAGATACG
GCTGTTTATTTTTGTGCGAAACACGAATCTGATAGTAGCAGTTGGCACACTGGGTGGAACTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG
pLcL-2-36L:
ATGGCCTGGACTCCTCTCCTCCTCACTCTCCTCGCTCACTGCACAGGGTCCTGGGCCCAGTCTGTGCTGACGCAGCCGTCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTC
ACCATCTCCTGCACTGGGAGCTACTCCAACATCGGGACAGGTTTTGATGTACACTGGTACCAGCATCTTCCAGGCAAAGCCCCCAAGCTCCTCATCTTTGGTAACAACAAT
CGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGCCTCCAGCCTGAGGATGAGGGTGACTATTACTGTCAGTCC
TTTGACAGTAGCCTGAGTGGTTCGAACGTCTTCGGGACTGGGACCAAGCTGACCGTCCTAA
V2-7
pHC-2-7H:
ATGAAGCACCTGTGGTTCTTCCTCCTGCTGGTGGCGGCTCCCAGATGGGTCCTGTCCCAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGACTTCGGAGACCCTG
TCGCTCACCTGCACTGTCTCTGGTGGCTCCATCAGAGGTGGGACTAACTACTGGGCCTGGATCCGCCAGCCCCCAGGGAAGGGGCCGGAGTGGCTTGGGAGTGTCTATTAC
AGTGGGAGCACCTACGACAACCCGTCCCTCAAGAGTCGAGTCAGCATATACGTAGACACGTCCAAGAACAAGTTCTCCCTGAGGCTGCGCTCTGTGACCGCCGCAGACACG
GCTATTTATTACTGTGCGAGACATGAATCTGATAGTAGTAGTTGGCACACTGGGTGGAACTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG
pLcL-2-7L:
ATGCCCTGGGCTCTGCTCCTCCTCACTCTCCTCGCTCACTGCACAGGGTCCTGGGCCCAGTCTATGCTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGACAGAGGGTC
ACCATCTCCTGCACTGGGAGCAGTACCAACATCGGGGCAGGTCTTGCTGTCCACTGGTACCAGCATCTTCCAGGAACAGCCCCCAAACTCCTCATCTATGGTAACACCAAT
CGGCCCTCAGGGGTCCCTGACCGCTTCTCTGGCTCCAAGTCTGGCACCACAGCCTCCCTGGCCATCACTGGGCTTCAGGCTGACGATGAGGCTGATTATTACTGCCAGTCC
TTTGACGGCAGCCTGAGTGGTTCGAACGTCTTCGGAACTGGGACCAAGGTGACCGTCCTCA
V3-2G6
pHC-3-2G6H:
ATGGACTGGACCTGGAGCGTCCTCTTTGTGGTGGCAGCAGCTACAGGTGTCCAGTCCCAGGTGCAGCTGGAGCAGTCTGGGGCTGAGGTGAAGAGGCCTGGGTCCTCGGTG
AAGGTCTCCTGCCAGACTTCTGGAGGCACCTTCAGCAGTTTTGCTTTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGGTGGGAGGGATCATCGGTATGTTT
GGGACAACAAGCTACGCACAGAAGTTCCAGGGCAGAGTCACGATTTCCGCGGACGAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGACGACACGGCC
ATATATTACTGTGCGAGAGGCAAGAAGTATTATCATGATACTCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG
pLck-3-2G6K:
ATGGAAGCCCCAGCTCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGAGAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAA
AGAGCCACCCTCTCCTGCAGGGCCAGTCAGATTGTTAGCAGCAGCCAGTTAGCCTGGTACCAGCATAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGCTGCATCCAGC
AGGGCCACTGGCATCCCAGACAGGTTCAGTGGTAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAG
TATGGTACCTCCCACGCTTTTGGCCAGGGGACCAAGCTGGAGATCAAAC
I8-1B6
pHC-8-1B6H:
ATGGACTGGACCTGGAGGGTCCTCTTTGTGGTGGCAGCAGCTACAGGTGTCCAGTCACAGGCGCAACTGGAGCAGTCTGGGGCTGAGGTGAGGAGGCCTGGGTCCTCGGTG
AAGGTCGCCTGCAAGACTTCTGGAGGCATCTTCAGTAATTTTGCTGTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATTCTCTCTATCTTT
CGTACAACAAACTACGCACAGAAATTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACATGGAGCTGAACAGCCTGAGATCTGACGACACGGCC
GTCTATTACTGTGCGAGAAGCATTACAAATCTTTACTACTATTACATGGACGTCTGGGGCAAGGGGACCACGGTCACCGTCTCCTCAG
pLcL-8-1B6L:
ATGCCCTGGGCTCTGCTCTTCCTCACCCTCCTTACTCAGGGCACAGGGTCCTGGGCCCAATCTGCCCTGACTCAACCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATC
ACCGTCTCCTGCACTGGAACCAACAGTGACGTTGGTACTTATAACTATGTCTCCTGGTTCCAGCAGCACCCAGGCGAAGCCCCCAAAGTCATAATTTTTGATGTCAGTCAT
CGGCCCTCAGGGGTTTCTAACCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGACTGAGGACGAAGCTGATTATTACTGCAGCTCA
TATACAACCAGCAACACTCGAGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAA
V3-3D2
pHC-3-3D2H:
ATGGACTGGACCTGGAGGGTCCTCTTTGTGGTGGCAGCAGCTACAGGTGTCCAGTCCCAGGTGCAGCTGGTCCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTG
AAGGTCTCCTGTAAGGCTCCTGGAGTCATCTTCAATGCCTATGCTATGAGCTGGGTGCGACAGGCCCCCGGACAAGGGCTTGAGTGGATGGGAGGGATCACCGGTGTCTTT
CACACAGCAACCTACGCACCGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGACGACACGGCC
GTGTATTACTGTGCGCGAGGACCCAAGTACTACCACTCCTACATGGACGTCTGGGGCGAAGGGACCACGGTCACCGTCTCCTCAG
(Continued)
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pLck-3-3D2K:
ATGGACATGAGAGCCCTCGCTCAGCTCCTGGGGCTCCTGCTGCTCTGTTTCCCAGGTGCCAGATGTGACATCCAGATGACCCAGTCTCCATCTTCACTGTCTGCATCTGTA
GGAGATAGAGTCACCATCACTTGTCGGGCGAGTCAGGACATTAGCAATTATGTAGCCTGGTTTCAACAGAAACCAGGGAAAACCCCTAAGTCCCTGATGTATGCTACATCC
AAATTGCAAAATGGGGTCCCTTCAAGATTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAACTTATTACTGCCAA
CAGTATAGTCGTTATCCTCCCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAC
V3-1G10
pHC-3-1G10H:
ATGGACTGGACCTGGAGCGTCCTCTTTGTGGTGGCAGCAGCTACAGGTGTCCAGTCCCAGGTGCAGTTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCCGGGTCCACGGTG
AAGGTCTCCTGCGAGGCTTCTGGAGTCACCTTCAATCACTATACTGTCAGCTGGGTGCGACAAGCCCCTGGACAAGGACTTGAATGGATGGGAGGGATCATCCCTCTCTTT
GGTACAGCAGACTACGCACAGAAGTTCCAGGACAGAGTCACAATTACCGCGGACAGATCCACGGGCACAGCCTACATGGAGCTGAGCTCCCTGAGACCTGAAGACACGGCC
CTGTATTACTGTGCGAGATCCGGAACTACGAAGACGAGATATAACTGGTTCGACCCCTGGGGCCAGGGAACCACGGTCACCGTCTCCTCAG
pLck-3-1G10K:
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACTCTTGGAGAAATAATAATGACGCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAA
AGAGTCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTGGCACCAACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCACCAGG
GCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGAGACAGAGTTCACTCTCAGCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCACTAT
AATAACTGGCCTCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAAC
I5-24
pHC-5-24H:
ATGGACTGGACCTGGAGCATCCTCTTTGTGGTGGCAGCAGCTACAGGTGTCCAGTCCCAATTCCAGTTGGTGCAATCTGGGGCTGAAGTGAGGAAGCCTGGGTCCTCGGTG
AAGGTCTCCTGCACGGCCTCTGGAGGCACCTTCAGTAGATACACTGTCAACTGGGTGCGACAGGCCCCTGGACAGGGACTTCAGTGGATGGGCAGGTTCATCCCTCTCCTT
GGTATGACAAACTACGCACAGAGGTTCCAGGGCAGAGCCACGATCACCGCGGACAAATCCACGACCACAGCCTTCTTGGAGCTGAGCAGCCTGACATCTGAGGACACGGCC
GTCTATTTCTGTGCGAGACATGATAGCAGTGGTTATCACCCTCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG
pLck-5-24K:
ATGGAAGCCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGAGACCACCGGAGAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGAGAA
AGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTCTTAGCAGCGGCCACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGC
AGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCGGTGTATTACTGTCAGCAA
TATGCTGTCTTTCTGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAAC
I4-128
pHC-4-128H:
ATGGACTGGACCTGGAGGGTCCTCTTTGTGGTGGCAGCAGCTACAGGTGTCCAGTCCCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTG
ATGGTCTCCTGCAAGGCCTCTGGAGGCACCTTCAGCACTTATGGTGTCAGCTGGGTGCGACAGGCCCCTGGACAAGGACTTGAGTGGGTGGGAGGAATCATCCCTATCTTT
GGTACAGCAAAATACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCTCGACCACAGCCTACATGGAGCTGAGCCGCCTGAGATCTGAGGACACGGCC
GTGTATTACTGTGCGAGGCCTAACACCTATGGTTACATACTGCCCGTCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG
pLck-4-128K:
ATGGACATGAGGGCCCCCGCTCAGCTCCTGGGGCTCCTGCTGCTCTGGCTCCCAGGTGCCAAATGTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTG
GGAGACAGAGTCACCATCGGTTGCCGGGCCAGTCAGACTATCAGTACCTACTTGGCCTGGTATCAGCAGGTGCCAGGGAAAGCCCCTAAACTCCTAATCTATATGGCGTCT
ACTTTAGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGGTGATTTTGCAACTTATTACTGCCAA
CATTATAACACTTATTCTTCTACTTTTGGCCAGGGGACCAAGCTGGAGATCAAAC
V4-17
pHC-4-17H:
ATGAAGCACCTGTGGTTCTTCCTTCTGCTGGTGGCGGCTCCCAGATGGGTCCTGTCCCAGTTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTG
TCCCTCACCTGCACTGTCTCTGGTGGCTCCATCACTAGGAATAGTTACTTCTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTATGTATTAT
GATGGGACCACCTACCACAACCCGTCCCTCAAGAGTCGACTCACCTTATCCGCGGACACGTCCAAGAACCAGTTCTCTGTGAGGCTGAGCTCTGTGACCGCCGCAGACACG
GCTGTCTATTACTGTGCGAGACATCATGTTACGGAGTTACGAGTTTTGGAGTGGTTACCTAAGTCTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG
pLcL-4-17L:
ATGGCCTGGATCGCTCTCCTCCTCACCCTCCTCACTCACTGTGCAGGGTCCTGGGCCCAGTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTC
ACCATCTCTTGTTCTGGAAGCAGCTCCAACATCGGAACTTATTATGTACACTGGTACCAACACCTCCCAGGAACGGCCCCCAAACTCCTCATCTATGATAATAATCAGCGG
CCGTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACTTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCCGAGGATGAGGCTGATTACCACTGTGCAGCATGG
GACGACAGCCTGAGTGGGGTGGTATTCGGCGGAGGGACCAAGCTGACCGTCCTAA
(Continued)
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V3-2C3
pHC-3-2C3H:
ATGGACTGGACCTGGAGGGTCCTCTTTGTGGTGGCAGCAGCTACAGGTGTCCAGTCCCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTG
AAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAACAACTATGCTGTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTT
GGTACAGCAAACTACGCACATAAGTTCCAGGGCAGAGTCACGATTACCGTGGACGAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCC
ATGTATTACTGTGCGAGAGTTTGTAGTTTCTATGGTTCGGGGAGTTATTATAACGTGTTCTGCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG
pLck-3-2C3K:
ATGGACATGAGAGTCCCCGCTCAGCTCCTGGGGCTCCTGCTGCTCTGGCTCCCAGGTGCCAAATGTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGCA
GGAGACAGAGTCACCATCACTTGCCGGGCCAGTCAGAGTATTAGTAGCTGGTTGGCCTGGTATCAGCAGAAACCGGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCT
AGTTTAGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAA
CACTATAATAGTTATTCTCAGACTTTTGGCCAGGGGACCAAAGTGGAGATCAAAC
Listed are the nucleotide sequences of the variable region, including the signaling sequence that were cloned into the appropriate expression vectors.
FIGURE 2 | Infection or vaccination with pdmH1N1 induces a dominant
antibody response targeting the HA stem. (A) mAbs to the HA stem fail to
inhibit hemagglutination but a minority of mAbs inhibit hemagglutination by
pdmH1N1. All mAbs were at 40μg/ml and diluted 50% with virus in the ﬁrst
well. No detectable hemagglutination means that hemagglutination was not
inhibited at 20μg/ml. (B) Anti-HA stem mAbs inhibit binding of a mouse mAb
(C179 (Okuno et al., 1993)) to the HA stem in a competition ELISA. Note that
mAb I5-52, not using IGHV1-69, also inhibited C179 binding. (C) pH 5
pre-treatment of HA selectively decreases binding of anti-HA stem mAbs
whether encoded by IGHV1-69 or other IGHV genes (like I5-52) but not
anti-HA head mAbs like V2-36. (D) ELISA showing competitive inhibition of
the indicated mAbs of the binding of biotinylated I5-24, which uses IGHV1-69
and binds to the HA stem. Note that V2-36 also inhibits binding of I5-24. Also
shown is competitive inhibition of I5-24 binding by I14-2B7 , which uses
IGHV1-18 and IGKV2-30. KE5, an human anti-HCMV monoclonal antibody
(McLean et al., 2005), was used as a negative control.
With a single intraperitoneal injection of 300μg, we saw signif-
icant increases in survival rates (Figure 5A). Sui et al. (2009),
pointed out that IGHV1-69 is the only germlineV-gene to encode
aPheatthetopof theCDRH2loopandthatthePhemakesseveral
criticalinteractionswithH5HA.SixallelesofIGHV1-69 (∗02,∗04,
∗08,∗09,∗10,and ∗11)haveaLeuinplaceof aPheinthisposition.
Our data on I5-24 show that an allele of IGHV1-69 that has a Leu
can bind strongly to the HA stem and can treat a lethal infection
withpdmH1N1(Figures2and5A).InadditionothermAbsusing
IGHV1-69∗02 or IGHV1-69∗04 bound to the HA stem (Table 1).
It is interesting that the ancestral gene probably encoded a Leu as
the only IGHV1-69 genes from the Chimpanzees,the Gorilla,and
the Orangutan encode a Leu at that position and these great apes
have respective common ancestors with humans 6, 10, and 12–16
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FIGURE 3 |Vaccines for seasonal inﬂuenza or pdmH1N1 and puriﬁed
recombinant HA from highly pathogenic avian H5N1 inﬂuenza exhibit
the epitope targeted by anti-HA stem mAbs. ELISA reactivity with the
2009/2010 seasonal inﬂuenza vaccine, the pdmH1N1 vaccine, and puriﬁed
recombinant ectodomain of the HA of an H5N1 avian inﬂuenza virus
A/Vietnam 1203/2004 (Clade 1) of 5 anti-HA stem mAbs (V3-2G6, I4-128,
I5-24, I8-1B6 using IGHV1-69 and I5-52 using IGHV1-18), with for comparison,
three anti-HA head antibodies (I4-1G8, V2-36, and V4-17).
FIGURE 4 | Neutralization of pdmH1N1 and the highly pathogenic avian
H5N1 inﬂuenzaA viruses by anti-HA stem mAbs. (A) Neutralization of
pdmH1N1 by mAbs present for the entire assay.Titrations commenced at a
concentration of 5μg/ml of each mAb.The most potent mAbs at
neutralization were V2-36 (against the HA head) and V3-2G6 (against the HA
stem), which inhibited infectivity completely at ∼40 ng/ml and ∼80 ng/ml.
Anti-HA stem mAbs not using IGHV1-69 like I14-2B7 , using IGHV1-18, and
V3-1B9, using IGHV3-11, also completely neutralized pdmH1N1. Neutralizing
titers against inﬂuenza virus A/Brisbane/59/07(H1N1) were 2- to 32-fold lower
in all cases (data not shown). No neutralization activity against Brisbane
inﬂuenza A/Brisbane/10/2007 (H3N2) by any mAb tested was observed (data
not shown), consistent with previous observations on mAbs using IGHV1-69
(Throsby et al., 2008; Sui et al., 2009). (B,C) Neutralization of infectivity of the
highly pathogenic Inﬂuenza A/Goose/Ger/R1400/07 (H5N1) avian virus. (B)
Shown are representative images of the plaque reduction assay performed
with inﬂuenza A virus A/Goose/Ger/R1400/07 (H5N1) and mAb I8-1B6
(5μg/ml). (C) Only V2-36 (which failed to bind to H5 HA, Figure 1) failed to
neutralize infectivity. (D) Anti-HA stem mAbs encoded by IGHV1-69 inhibit H5
HA-mediated fusion, correlating with low binding to the HA of highly
pathogenic avian inﬂuenza A/Hong Kong/156/197 (H5N1) virus (Figure 1).
Note the decreased syncytia formation in wells treated by the anti-stem mAb,
C179, or the IGHV1-69-using mAbs, I4-128, I8-1B6, and V3-2G6, in contrast to
the control with no antibody added (no Ab) and the anti-HA head mAb, V2-36,
which did not bind to this H5 HA.
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FIGURE 5 |Therapeutic effects of mAbs on lethal infections with a
human isolate of pdmH1N1. (A,B) Groups of 5 CD-1 mice were infected
intranasally with 2×10
5 PFU of A/Halifax/210/2009 (pdmH1N1).Twenty-four
hours post-infection, the mice were treated IP with (A) 300μgo ft h e
indicated anti-HA stem mAbs (the survival curves forV3-2G6 and I8-1B6 are
superimposed and mainly superimposed with the curve of I4-128) or (B)
with the indicated doses of the anti-HA head mAb, V2-36.
million years ago (Scally et al., 2012). Treatment with an anti-
HA head mAb,V2-36, with a dose of 180μg( ∼9mg/kg) also was
successful in treating mice infected with pdmH1N1 (Figure 5B).
MANY OF THE mAbs WERE DERIVED FROM MEMORY B CELLS INDUCED
BY SEASONAL INFLUENZA BUT SOME MAY HAVE BEEN DERIVED FROM
NAÏVE B CELLS
The PB that entered the blood ∼7–10days after infection or vac-
cination with pdmH1N1 were likely induced by cross-activation
by pdmHA of memory B cells, as the median number of somatic
mutations in the IGHV gene was 29 versus 13.6±4.8 in memory
BcellsorgerminalcenterBcells(Wrammertetal.,2008;Figure6).
All but one of the mAbs,V4-17, cross-reacted with the 2009/2010
seasonal inﬂuenza vaccine (Figure 3). Thus it is likely that these
memoryBcells,includingthoseagainsttheHAstem,wereelicited
by previous contact with seasonal inﬂuenza (Corti et al., 2010).
A minority of the mAbs (12.5%) exhibited equal to or less than
six somatic mutations (Table 1) and thus were likely to be ulti-
mately derived from naïve B cells activated by pdmHA (Smith
et al., 1997). Four mAbs were against the HA stem and two used
FIGURE 6 | Evidence that most mAbs originated from memory B cells
that were activated by pdmH1N1. Shown are the number of somatic
mutations in IGHV genes of mAbs generated from PB and memory B cells.
Whiskers show the 5/95th percentile. Mann–Whitney Rank SumTest of the
number of somatic mutations in IGHV genes of mAbs generated from
memory B cells (N =23) versus PB (N =25) demonstrates a signiﬁcant
difference (p <0.001). Note that more than 50% of the mAbs generated
from PB (which all but one cross-reacted with seasonal inﬂuenza vaccine)
exhibited IGHV genes with more than 10% of their nucleotides mutated
(>28 mutations), with the median number of mutations being 29.
IGHV1-69. Given that these mAbs were from a different clono-
type (Table 1), this observation suggests that a primary response
against inﬂuenza, includes heterosubtypic antibodies against the
HA stem.
ANALYSIS OF THE RESPONSE OF SUBJECT V2
We analyzed the frequency of anti-HA stem mAbs generated from
each subject (Table 3). We found at least one anti-HA stem mAb
from each subject with one exception, V2 who was healthy and
was vaccinated with pdmH1N1 vaccine and expressed at least one
IGHV1-69 gene (data not shown). If we assumed that the fre-
quency of anti-HA stem mAbs using IGHV1-69 in responses to
pdmH1N1is50%,theprobabilityof obtainingtheobservedresult
fromV2 by chance alone was 0.002 and thus, unlikely (Table 3).
We sought a cause for this and we noted that the antibody
response of V2 to pdmH1N1 vaccine had two similarities to the
antibody response of humans to the seasonal inﬂuenza vaccine.
Firstly,eightof ninemAbsfromV2blockedhemagglutinationand
were therefore directed against the HA head and used IGHV4-39.
Second,seven of these belonged to the same clonotype (Figure7)
andtheother,V2-12,alsousedIGHV4-39 butuseddifferentIGHD
and IGHJ genes, and used an IGKV rather than IGHL gene. We
know that the dominant clonotypic response against the HA head
inV2wassimilartoresultsobtainedaftervaccinationwithseasonal
inﬂuenza(Wrammertetal.,2008).ThedominantclonotypeinV2
had a high number of somatic mutations in IGHV4-39 ranging
from 21 to 34 (Table 1) indicating they were derived from mem-
ory B cells that had been activated to differentiate to PB by the
HA of pdmH1N1. That all of the mAbs from this subject, V2,
bound to seasonal inﬂuenza vaccine (Table 1), suggested that the
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Table 3 | Expected versus observed IGHV1-69 usage per subject.
Subject No. of anti-pdmHA mAbs Frequency
(%)
*Probability of
observed result
Total Using IGHV1-69
I3 1 1 100 0.04
I4 7 2 29 0.03
I5 4 3 75 0.0002
I8 1 1 100 0.04
I14 5 1 20 0.2
V3 14 12 86 1E−15
V4 7 5 71 2E−6
V2 9 0 0 0.7
Notethatallbuttwooftheeightsubjects(V2andI14)hadagreaterthanexpected
frequency of IGHV1-69-using mAbs than would be expected by chance.The total
proportion of mAbs using IGHV1-69 was 52% (95% conﬁdence intervals of 38–
66%). If it is hypothesized that in the response to pdmH1N1, IGHV1-69 is used in
52% of mAbs, the probability that the results obtained with subjectV2 occurred
by chance was only 0.002, whereas for I14 the chance was 0.16 (i.e., was likely).
*Based on the average frequency of usage of IGHV1-69 in human antibodies of
4% (De Wildt et al., 1999).
memory B cells had been induced by a seasonal H1N1 inﬂuenza
virus or a related virus. Consistent with this,V2 was aged over 60,
and had likely been in contact with an inﬂuenza virus related to
the pdmH1N1 (Hancock et al., 2009). Thus, in V2, the lack of a
prominent response to the pdmH1N1 vaccine of antibodies using
IGHV1-69, correlated with a dominant antibody response against
the HA head, similar to that which occurs in seasonal inﬂuenza
(Wrammert et al.,2008,2011).
EVIDENCE THAT HUMAN VACCINATION WITH pdmH1N1 PROVIDES
PASSIVE IMMUNITY THAT PROTECTS MICE AGAINST LETHAL
INFECTION WITH H5N1 INFLUENZA VIRUS
We next asked whether the dominant cross-protective antibody
response in memory B cells induced by vaccination with the
pdmH1N1 vaccine correlated with circulating cross-protective
antibodies in human plasma. To test the protective effect of the
human plasma from a subject vaccinated with pdmH1N1 vac-
cine, we passively transferred human plasma to mice and subse-
quentlygavethemalethalintranasaldoseof aheterologousH5N1
inﬂuenza virus. We tested the ability of plasma from donor V3
taken 14days and 1year after vaccination to protect mice against
a lethal infection with H5N1 inﬂuenza (Figure 8A). We used as
a control, plasma from a young adult donor taken in 2006, to
ensure the subject could not have been in contact with the 2009
pandemic H1N1 virus. We observed that 400μl of plasma from
V3 taken 14days after vaccination completely protected the mice
from a lethal infection with H5N1 inﬂuenza. We also observed
that 400μl of plasma from V3 collected a year after the vacci-
nation protected mice against death from a lethal infection with
H5N1 inﬂuenza. The protection seemed to wane after a year after
thevaccination,asalthoughallofthemicetreatedwiththisplasma
survived, the infection with H5N1 produced a small weight loss.
However three times the dose of human plasma from V3 taken
1yearaftervaccination(whichgavemuchlowerconcentrationsof
human immunoglobulins in the mice than in the donor’s plasma)
protected the mice against signiﬁcant weight loss (Figure 8A).
The cross-protective, heterosubtypic antibodies were probably
againstaconservedsiteontheHAstem.Thiswassupportedbythe
results of ELISA assay of theV3 plasma against untreated and pH
5-treated HA of H9. The titer of the plasma against pH 5-treated
H9 HA was drastically reduced, consistent with most of the het-
erosubtypic antibodies being against the conserved site on the HA
stem (Figure 8B).
EVIDENCE THAT A mAb GENERATED FROM A HUMAN VACCINATED
WITH pdmH1N1 PROTECTS AGAINST AND IS AN EFFECTIVE
THERAPEUTIC FOR MICE WITH A LETHAL INFECTION WITH A
HETEROLOGOUS H5N1 INFLUENZA VIRUS
WetookourmostpotentmAbanti-HAstemmAbgeneratedfrom
asubjectvaccinatedwithpdmH1N1andtestedthedosethatcom-
pletely protected against a lethal infection with H5N1 inﬂuenza.
As can be seen (Figure 9A), very low doses (5μg i.p.) completely
protected mice from death. A higher dose (15μg i.p.) completely
protected against weight loss. This established that antibodies
against the HA stem that were induced by pdmH1N1 vaccination
mediated protection against a heterologous H5N1 inﬂuenza.
We tested whether the same mAb had therapeutic effects on a
lethal infection with a heterologous H5N1 inﬂuenza (Figure 9B).
As can be seen 24h after infection with H5N1 inﬂuenza virus,
when the mice were obviously severely ill and had loss ∼10% of
their weight, administration of V3-2G6 at either 150 or 300μg
completely cured the mice. We also delayed therapy for an addi-
tional24h,at48hafterinfectionwithH5N1inﬂuenzavirus,when
the mice had lost more than 20% of their weight. The administra-
tion of V3-2G6 at either 150 or 300μg completely cured the mice.
Shown in Figure 9C, is a dose–response experiment which shows
that 75μg cured all of the mice from a lethal infection with H5N1
inﬂuenza virus.
DISCUSSION
Our data show that vaccination with the pdmH1N1 vaccine or
infection with the virus, induced in many humans a dominant
cross-protective, heterosubtypic antibody response against a con-
served site on the HA stem. The majority of the anti-HA stem
mAbswereencodedbyIGHV1-69 butaminoritywereencodedby
different immunoglobulin variable region genes, which may bind
todifferent,overlappingepitopes.Thiswasconsistentwiththefact
thatthepandemicvaccineexhibitedtheconservedepitopesbound
byanti-HAstemmAbs(Figure3).Incontrast,comparableexperi-
mentsexaminingthefrequencyof anti-HAstemmAbsinhumans
afterseasonalinﬂuenzavaccination,foundonlyantibodiesagainst
the HA head and no mAbs against the HA stem (Wrammert et al.,
2008)orfound,insomeindividuals,verylowfrequenciesof mem-
ory B cells making heterosubtypic, cross-protective mAbs (Corti
et al., 2010). This was despite the fact that, as we showed, the
seasonal inﬂuenza vaccine exhibited abundantly the conserved
epitopes recognized by mAbs against the HA stem (Figure 3).
Unlike the seasonal inﬂuenza vaccine, the pdmH1N1 vaccine, in
our experiments, was administered with the AS03 adjuvant sys-
tem (Moreletal.,2011).However,wegeneratedtwomAbsagainst
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IGHV4-39*01
V2-12
V2-36
V2-11
V2-2 V2-3
V2-7
V2-4
V2-38
V4-17
IGHV4-39*01 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTY 60
V4-17 QLQLQESGPGLVKPSETLSLTCTVSGGSITRNSYFWGWIRQPPGKGLEWIGSMYYDGTTY 60
V2-4 QLHLQGSGPGLVKPSETLSLTCTVSGGSISRNTHFWAWIRQPPGKGLEWIGSIYYSGGTY 60
V2-38 QLLLQGSGPGLVKPSGTLSLTCTVSGGSISRNTHFWAWIRQPPGKGLEWIGSIYYSGGTY 60
V2-36 ELRLHESGPGLVKPSGTLSLTCTVSGGSISGGSHYWAWIRQSPGKGLEWIGSIYYSGSTY 60
V2-11 QLQLQESGPGVVKPSETLSLTCTVSGGSISGGSHYWGWIRQTPGKGLEWIGSIYYSGSTY 60
V2-2 QLRLQESGPGLVKPSETLSLTCTVYGDSISRGPHYWAWIRQSPGKGLEWIGSVYYSGSTY 60
V2-3 QLQLQESGPGLVKPSETLSLTCTVYGDSIRRGPHYWAWIRQPSGKGLEWIGSVYYSGATY 60
V2-7 QLQLQESGPGLVKTSETLSLTCTVSGGSIRGGTNYWAWIRQPPGKGPEWLGSVYYSGSTY 60
V2-12 QLQLQESGPRLVRPSETLSLTCTVSGGSIRGGGSFWAWIRQPPGRGLEWIASVYYSGSSY 60
:* *: *** :*:.* ******** *.** . :*.****..*:* **:.*:**.* :*
IGHV4-39*01 YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAR--------------------- 99
V4-17 HNPSLKSRLTLSADTSKNQFSVRLSSVTAADTAVYYCARHHVTELRVLEWLPK-SDYWGQ 119
V2-4 DNPSLRSRISMSVDTSKNQFSLRLRSVTAADTAVYYCARHVSDGSSWHTGWNW-FDPWGQ 119
V2-38 DNPSLRSRVAMSVDTSKNQFSLRLRSVTAADTAVYYCARHVSDGSSWHTGWNW-FDPWDQ 119
V2-36 DSPSLKSRLSMSVDKSKNQFHLTLRSVTAADTAVYFCAKHESDSSSWHTGWNW-FDPWGQ 119
V2-11 DNPSLKRRVTMSVDRSKNQFSLKLNSVTAADTALYYCARHESDSSSWHTGWNW-FDPWGQ 119
V2-2 DNPSLKSRVSISVDKSKNQFSLKVRSVTAADTAIYYCAKHESDTSSWHTGWNW-FDPWGQ 119
V2-3 DNPSLRSRATISVDTSKNEFSLRLNSVTAADTAIYYCAKHESDDSSWHTGWNW-FDPWGQ 119
V2-7 DNPSLKSRVSIYVDTSKNKFSLRLRSVTAADTAIYYCARHESDSSSWHTGWNW-FDPWGQ 119
V2-12 DNPSLRSRITLSVDMSKSQFSLRLNSVTAADTAIYYCARHPPDYSYENRGRPYYFDYWGR 120
.***: * :: .* **.:*::* * * * * * **:*:**:
A
B
FIGURE 7 |The dominant clonotype of mAbs against the HA head
generated from subjectV2. (A) Shown are alignments of the amino acid
sequences of the variable region of the H chain of the dominant clonotype
from V2 using the IGHV4-39, another mAb against the HA head from V2 also
using IGHV4-39, and a mAb against the HA head from V4 also using
IGHV4-39. We also included the amino acid sequence encoded by the
germline IGHV4-39*01 allele to indicate somatic mutations. Note that the
mAbs in red belong to the same clonotype as seen by the common
IGHD-6-13-, IGHJ-5-encoded residues (and the similar light chains,Table 1).
Shown in (B) is a phylogram using the Clustal-W website.
pdmHA from a subject vaccinated with unadjuvanted pdmH1N1
vaccine and one of the mAbs used IGHV1-69 (unpublished data).
Thusitseemsthattheadjuvantisnotresponsibleforthepredomi-
nance of the heterosubtypic antibodies induced by the pdmH1N1
vaccine,but this will need to be investigated further.
WhatwasthedifferencebetweenthepdmH1N1vaccine,which
induces a dominant cross-protective antibody response against
the conserved HA stem, and seasonal inﬂuenza vaccines, which
induce a dominant, isolate-speciﬁc response against the mutable
HA head? It is unlikely that the intrinsic nature of the pdmH1N1
antigen or its presentation to the immune system (Wei et al.,
2010)wasafactorinthedominanceof theanti-HAstemantibody
responsetopdmH1N1,asthisoccurredinsubjectswithinfections
and vaccinations with pdmH1N1. Infections and vaccinations
involve many differences in the presentation and nature of the
antigen (in infections it was produced by human cells,in vaccines,
in hens’eggs),the site of the immune response,and the associated
inﬂammatoryresponses.Theprobablemechanismthroughwhich
the seasonal inﬂuenza vaccine fails to induce an effective cross-
protective anti-HA stem antibody response and only induces an
undetectable (Wrammert et al., 2011) or ineffectual (Corti et al.,
2010) heterosubtypic response, was elucidated by the detailed
dissection of the antibody response of subject V2. This subject
responded to the pdmH1N1 vaccine like a seasonal inﬂuenza vac-
cine, with a dominant clonotypic antibody response against the
HA head, which inhibited hemagglutination (Figure 2A). That
there was an inverse correlation with the frequency of antibod-
ies against the HA stem with the activation of memory B cells
against the HA head in V2, is most plausibly explained by ele-
gant experiments that have documented the competition between
B cells for presenting antigen to T-cell helpers (Schwickert et al.,
2011). The data show that, in V2, the pdmH1N1 vaccine acti-
vated the dominant clonotype of memory B cells against the HA
head which differentiated into PB. These activated B cells would
have physically outcompeted (Schwickert et al., 2011) those rare
memory B cells against the HA stem in presenting cross-reactive
peptides shared between virus subtypes (Russell and Liew, 1979;
DohertyandKelso,2008)tohelperTcells(Schwickertetal.,2011).
The same thing would happen in normal humans vaccinated with
the seasonal inﬂuenza vaccine, where it has been demonstrated
that the vaccine activates pauci-clonal memory B cells against the
HA head (Wrammert et al., 2008). In contrast, in most subjects
infected or vaccinated with pdmH1N1, there was a paucity of
memory B cells that were activated by the pdmHA head. Even if a
few memory B cells had low afﬁnity for the pdmHA, they would
not compete for T-cell help with memory B cells making higher
afﬁnity antibodies against the HA stem (Schwickert et al., 2011).
We also showed evidence that probable naïve B cells which have
a diminished ability to interact with T cells than memory B cells
(Tangye and Tarlinton, 2009), were activated by the HA stem of
pdmH1N1 and collaborated with helper T cells. This is probably
because, in the absence of memory B cells that were activated by
the HA head of the pdmH1N1, the naïve B cells could competi-
tively present antigens to the memory T cells induced by shared
peptidesbetweenvirionproteins(RussellandLiew,1979;Doherty
and Kelso, 2008).
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FIGURE8|P r o p h ylactic effects of human plasma from a vaccinated
subject against lethal infections with H5N1 avian inﬂuenza virus. (A)
Twenty-four hours before intranasal infection of BALB/c mice with 2×10
5 PFU
of A/Hong Kong/213/2003 (H5N1) virus, groups of ﬁve mice were treated with
a4 0 0μl intraperitoneal injection of PBS as a control, or 400μl of plasma
collected from subject V3 either 14days after pdmH1N1 vaccination or 1year
after pdmH1N1 vaccination, and as a control, plasma from a young individual
unvaccinated and uninfected with pdmH1N1, collected in 2006. Another
group of ﬁve mice were pre-treated 72, 48, and 24h prior to infection with
400μl of plasma from V3 collected 1year after pdmH1N1 vaccination. (B) pH
5 treatment of H9 HA drastically decreases the binding of V3 sera compared
with binding of H9 HA treated at pH 7 .4.
Wrammert et al. (2011), observed that the sole mAb against
pdmHA that they had isolated from a critically ill donor was
speciﬁc for only pdmH1N1 and not for other H1N1 viruses;
they speculate that the reason this donor may have had more
serious illness was that they had fewer cross-reactive memory
B cells. Our results are consistent with this notion. Subject
I14 spent 2weeks in an intensive care unit and only two out
of ﬁve of the anti-pdmHA mAbs generated from this donor
were against the HA stem. One mAb used IGHV1-69 with
10 mutations, and another used IGHV1-18 with 3 mutations.
Thus, our results and those of Wrammert et al. (2011), sug-
gest that the number of heterosubtypic memory B cells cor-
relates with protection against serious inﬂuenza infection. This
supports the protection afforded by these heterosubtypic anti-
bodies and highlights the utility of inducing them using vac-
cines.
Our results show that a conventionally prepared inﬂuenza vac-
cine can induce in humans, broadly cross-protective antibodies
against the HA stem. Our results suggest that the unusual dom-
inance of the cross-protective antibodies against conserved sites
on the HA stem induced by pdmH1N1, was due to the absence
of memory B cells which are activated by the HA head of the
pdmH1N1. The one subject, V2, that had a high frequency of
memory B cells making hemagglutination inhibitory antibodies
against the HA head of pdmH1N1, did not make an IGHV1-69-
using mAb against the HA stem. This suggests a novel vaccination
strategy, namely to vaccinate with conventional vaccines against
inﬂuenza A viruses with HA that have not been circulating in
humans. Based on our results with the pdmH1N1 vaccine, this
strategy,withtheappropriatechoiceofvaccinestrainsfromGroup
1andGroup2of theHAnotcirculatinginhumans,shouldinduce
antibodies against all conserved epitopes on the HA stem includ-
ingthoseagainstepitopessharedbyvariousGroup1HAsubtypes
targetedbyIGHV1-69 encodedmAbs(Ekiertetal.,2009;Suietal.,
2009), epitopes shared by various Group 2 HA subtypes (Ekiert
et al.,2011),and epitopes shared by all 16 Group 1 and 2 HA sub-
types(Cortietal.,2011).Additionallytheremaybemanyothersyet
tobedeﬁned,forexample,targetedbythenon-IGHV1-69 anti-HA
stemmAbswehavedocumentedhere,orontheHAhead(Yoshida
etal.,2009).Howeverallof thereportedepitopesareaccessibleon
puriﬁed HA and also on infectious viruses, as mAbs against them
neutralize infectivity (Sui et al., 2009; Corti et al., 2011; Ekiert
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FIGURE 9 |Therapeutic and prophylactic effects of puriﬁed mAb
against lethal infections with H5N1 avian inﬂuenza virus. (A)
Twenty-four hours before intranasal infection with 2×10
5 PFU of
A/Hong Kong/213/2003 (H5N1) virus, three groups (ﬁve mice each) of
BALB/c mice were injected intraperitoneally with PBS as a control, or
15 or 5μg of V3-2G6 generated from a subject vaccinated with the
pdmH1N1 vaccine.The data shows survival rates and average weight
at over 14days. (B,C) Groups of ﬁve mice were infected intranasally
with 2×10
5 PFU of A/Hong Kong/213/2003 (H5N1) virus and (B)
treated after 24h with 150 or 300μg of V3-2G6 or after 48h with 300
or 600μg of V3-2G6 and (C) treated after 24h with 150, 75 or 37 .5μg
of V3-2G6.
et al., 2011). It would be interesting to see whether the broadly
cross-protective mAbs that bind to Group 2 HA subtypes (Ekiert
etal.,2009)orall16Group1and2HAsubtypes(Cortietal.,2011)
bind to conventional vaccines.We predict that they will. The mAb
that neutralized inﬂuenza viruses from all 16 HA subtypes was
generated from a subject infected with pdmH1N1 (Corti et al.,
2011), supporting the present demonstration that immunization
with an “antigen-shifted” HA of pdmH1N1 results in the acti-
vation of rare heterosubtypic memory B cells. Also supporting
our vaccination strategy is that this mAb that neutralized all 16
subtypes of HA, evolved from an antibody that neutralized only
Group1,butlateracquiredmutationsthatalsoneutralizedGroup
2 subtypes of viruses (Corti et al., 2011). Our vaccination strat-
egy should be suitable for all ages; our demonstration that the
primary antibody response to a“new”antigenic HA includes het-
erosubtypic antibodies probably originating from naive B cells,
indicates that young children should respond to a series of these
vaccinations.
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Kaur et al. (2011),reviewed advances in inducing broadly neu-
tralizing antibodies against inﬂuenza. One strategy that induced
broadly neutralizing antibodies against the HA stem was an initial
DNAvaccinationwithanHAinnaïvemice,ferretsornon-human
primates followed by immunization with an identical HA using
the seasonal inﬂuenza vaccine or an adenovirus vector (Wei et al.,
2010). The DNA vaccination was thought to act by increasing the
numberofhelperTcells.Ourresultssuggestthatitwillfailinadult
humans,duetotheplethoraof memoryBcellspresentinhumans
against the HA head induced by previous contact with related
inﬂuenza viruses. However, as foreshadowed by Wei et al. (2010),
DNA vaccination with HA may be useful to increase T helper cells
in children and memory B cells against the HA stem, in combi-
nation with our strategy of using conventional vaccines including
HA from inﬂuenza viruses not circulating in humans. The second
prime-boost strategy reviewed by Kaur et al. (2011), was funda-
mentally different from Wei et al. (2010), because it was based
on immunizing sequentially with different antigenically drifted
H3 HA spanning the past 40years since H3 appeared in humans
(Wang et al., 2010). The frequency of broadly neutralizing mAbs
in their experiments was low (3 out of 120 mAbs or 2.5% and it
was not clear whether the 3 mAbs were a clonotype; Wang et al.,
2010) and potency of their best mAb was >2 logs less potent at
preventing disease in mice than our best human mAb induced by
vaccination with pdmH1N1 vaccine. This is probably because rel-
atively few anti-HA stem mAbs were induced in the mice because
they immunized in the chronological order that these drifted
inﬂuenzastrainsarose,whichmimicksthehumanexperiencewith
H3N2. Each subsequent immunization would activate low afﬁn-
ity memory B cells against the HA head and these memory B cells
wouldout-competeforT-cellhelpthememoryBcellsagainstcon-
servedsitesontheHAstem.Howeverthiswasanimportantpaper
because it is the ﬁrst demonstration of broadly neutralizing mAbs
against the HA stem of Group 2 HA subtype inﬂuenza viruses.
With subsequent examples of human mAbs broadly neutralizing
against Group 2 HA subtypes of inﬂuenza viruses (Ekiert et al.,
2011)a n da l l1 6G r o u p1a n d2H As u b t y p e s( Corti et al., 2011),
there is hope that sequential vaccination with Group 1 and 2 sub-
types of HA that are not circulating in humans and have not been
exposed to the subject will induce broadly cross-protective anti-
bodies. Kaur et al. (2011), were enthusiastic about a minimalist
approach of designing new immunogens that had the conserved
protective epitopes and excluded the variable regions. Although
progress has been made, our demonstration that a conventional
vaccine that was developed and registered in less than 6months
induces broadly neutralizing antibodies may lead the way to a
faster and cheaper universal inﬂuenza vaccine rather than devel-
oping a new immunogen which will require extensive testing and
investment.
Further experimental and epidemiological studies need to be
undertaken on cross-protective antibodies in the sera after the
ﬁrst pdmH1N1 vaccination and vaccination with other strains
of inﬂuenza virus not circulating in humans, like H5N1. More-
over, there is a need to develop a simple and reliable serum
test that can predict heterosubtypic protection. The WHO stan-
dard neutralization assay and the hemagglutination inhibition
assay are inadequate to monitor the degree of protection in
serum induced by this new vaccination strategy. Although we
demonstrated that circulating antibodies in a human after vac-
cination with pdmH1N1 can provide passive protection to mice
from a lethal infection with H5N1 inﬂuenza virus, this is not
a practical assay. Binding assays, for example with an ELISA
against a heterologous HA, are poor at discriminating between
high levels of low afﬁnity antibodies and low levels of high
afﬁnity antibodies and cannot predict protection. As well, our
results show that competitive ELISA’s with an anti-HA stem mAb
(Corti et al., 2010; Wei et al., 2010) have to be cautiously inter-
preted due to false positives resulting from steric interference
from antibodies against the HA head. Pica et al. (2012) recently
developed chimeric hemagglutinin constructs and demonstrated
that patients infected with the pdmH1N1 virus had signiﬁcant
increases in their titers of anti-stem antibodies, supporting our
conclusions.
The demonstration that a conventional vaccine given safely to
millionsofhumansinducesadominant,cross-protectiveantibody
response against the HA stem given by us and others (Pica et al.,
2012),pointstoareadilytestablevaccinationstrategyforinducing
broad-spectrum protective antibodies against inﬂuenza by vacci-
nating successively with conventional vaccines or live attenuated
viruses based on inﬂuenza viruses with an “antigen-shifted” HA
that humans have not been exposed to.
MATERIALS AND METHODS
COLLECTION OF BLOOD SAMPLES AND PBMC ISOLATION
Twentyto50mlsamplesofvenousbloodwerecollectedfromindi-
viduals conﬁrmed to have had pdmH1N1 infections (veriﬁed by
RT-PCRof nasopharyngealswabs)orfromindividualsvaccinated
withthepdmH1N1vaccine.Bloodsampleswerecollectedforgen-
eration of mAbs from PB at 7–10days after vaccination or 7days
after onset of clinical symptoms with infection with pdmH1N1,
or for generation of mAbs from memory B cells 14days after vac-
cinationor2–8weeksafterinfection.Mononuclearcells(PBMCs)
and plasma samples were prepared using Ficoll–Hypaque were
aliquotedandfrozen.ThesestudieswereapprovedbytheResearch
Ethics Boards of the University of British Columbia and the Uni-
versity of Toronto. Infected subjects I4 and I5 were male and I3,
I8, and I14 were female and were respectively aged 23, 23, 49, 55,
and 41years. I4 and I5 were managed as outpatients and only I14
was seriously ill and was in the intensive care unit for 2weeks.
Vaccinated subjects had been immunized with pdmH1N1 with
Arepanrix™ H1N1 AS03-Adjuvanted H1N1 Pandemic Inﬂuenza
Vaccine. V2, V3, and V4 were all male and aged 63, 26, and 42.
Samples were collected between May and December 2009 and all
subjects gave informed consent. All subjects had been previously
vaccinated with the seasonal inﬂuenza vaccine but none more
recently than the preceding winter.
GENERATION OF mAbs
We collected blood from convalescent patients with conﬁrmed
infectionswithpdmH1N1andusedRT-PCRtoamplifyandclone
thecDNAencodingtheantibodiesmadebyindividual,newlygen-
eratedplasmablasts(PB)intheblood,andexpressedthemasmAbs
(Babcook et al., 1996). However, because it was not known that
the PB entered the blood after an infection rather than remaining
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in the site of infection, we also generated mAbs from memory B
cells in blood. When the pdmH1N1 vaccine became available in
November2009,wealsocollectedbloodfromvaccinatedsubjects.
FLOW CYTOMETRY
PBMCs were thawed, washed in PBS containing 2% BSA and
held for 30min on ice with labeled antibodies. For PB isola-
tion, the antibodies used were against the following antigens
conjugated with the following ﬂuorochromes: CD19-APC-H7,
CD3-FITC, IgM-FITC, CD20-FITC, CD27-PE, and CD38-PE–
Cy7. For memory B cell isolation, CD19-APC-H7, CD3-FITC,
IgM-FITC,and CD27-PE were used.All antibodies were from BD
Biosciences,with the exception of the IgM-FITC (Beckman Coul-
ter). For the isolation of pdmHA-binding PB, puriﬁed pdmHA
labeled with Alexa-647 was added to the antibodies. For the iso-
lation of pdmHA-binding memory B cells, pdmHA labeled with
Alexa-647 and biotin-conjugated e-pdmH1 HA were mixed with
the antibodies and streptavidin-PE–Cy7 (Invitrogen) was sub-
sequently added following a wash step. To purify PB, PBMCs
were ﬁrst gated on CD19pos/CD20neg/CD3neg/IgMneg cells, then
on CD27high/CD38high cells according to the known pheno-
type of PB (Medina et al., 2002; Odendahl et al., 2005) and in
the indicated cases pdmHA-binding PB were isolated. The PB
were individually deposited into PCR tubes containing RT-lysis
buffer and frozen at −80˚C. Memory cells were isolated by ﬁrst
gating on CD19pos/CD3neg/IgMneg cells, and then on CD27high
cells,and then on cells double-labeled with Alexa-647-conjugated
and biotin-conjugated pdmHA, the latter identiﬁed by binding
of streptavidin-PE–Cy7. Single pdmHA-binding B memory cells
were sorted into individual wells on 96-well plates. Each well con-
tained 50,000 irradiated EL4 cells supplemented with 5% T-cell
supernatant to induce expansion and differentiation into plas-
mablasts as described (Wen et al., 1987). After 1week wells were
screened for the production of pdmHA-speciﬁc antibodies by
ELISA.
AMPLIFICATION, CLONING, EXPRESSION, AND PURIFICATION OF mAbs
Individual PB were just lysed, but RNA was puriﬁed using the
AbsolutelyRNAMicroprepKit(Stratagene)fromclonesthatwere
generated from individual memory B cells. cDNA from PB or
clones was synthesized using constant region primers with Super-
Script III Reverse Transcriptase (Invitrogen) followed by PCR-
ampliﬁcation using Platinum pfx and Platinum Taq DNA Poly-
merase (Invitrogen). Sequences were determined on at least three
clones and immunoglobulinV-gene usage and somatic mutations
weredeterminedbyuseof theIMGTwebsite(Lefrancetal.,1999).
Restrictionsitesforcloningintotheheavy-andlight-chainexpres-
sion vectors (PHC and PLC) were included in the PCR primers as
previously described (McLean et al., 2005). The heavy- and light-
chainexpressionplasmidswereco-transfectedintoBOSC293cells
and the antibodies puriﬁed using Protein A Sepharose as before
(McLean et al.,2005).
PRODUCTION, PURIFICATION AND LABELING OF TRIMERIC SOLUBLE
pdmHA (pdmHA)
The H1N1 inﬂuenza virus (A/California/04/2009,accession num-
ber GQ117044) hemagglutinin (H1 HA) cDNA was kindly pro-
vided by Dr. Ruben Donis of the CDC (Atlanta, GA, USA). A
fusion protein containing the extramembranous region of the HA
(residues18-520)followedbythebacteriophageT4ﬁbritinfoldon
domainandthe3xFLAGtagwassecretedfromHEK293Tcells.The
puriﬁed trimeric fusion protein was desialylated with Sialidase A
(Prozyme, USA) and then labeled with either DyLight 649 NHS
ester or Sulfo-NHS-LC biotin (Pierce, USA), followed by limited
trypsin(Sigma,USA)cleavagetogiveamixtureof bothuncleaved
(HA0) and cleaved (HA1/HA2) soluble trimers.
ELISA
Monoclonal antibodies were screened by evaluation of bind-
ing to recombinant pdmHA in an ELISA. Ninety-six well
plates were coated with 50μl of puriﬁed recombinant pdmHA
(6μg/ml) or puriﬁed recombinant ectodomain of the HA of
an H5N1 avian inﬂuenza virus A/Vietnam 1203/2004 (Clade
1) from Protein Sciences Corporation (1μg/ml). Primary anti-
bodies, either in transfected cell supernatants or puriﬁed IgG,
were added for 1.5h at 37˚C, washed, and detected using goat-
anti-human IgG-AP (SouthernBiotech). To evaluate the binding
of the identiﬁed antibodies against the HA subtypes present
in recent inﬂuenza vaccines, 96-well plates were coated with
either the pdmH1N1 vaccine (Arepanrix™ H1N1, but with-
out the adjuvant) at 2μg/ml, or the 09/10 seasonal inﬂuenza
vaccine “Inﬂuvac™” (Solvay Pharma) containing three dif-
ferent HA subtypes (A/Brisbane/59/2007 (H1N1)-like strain,
A/Brisbane/10/2007 (H3N2)-like strain, B/Brisbane/60/2008-like
strain at 6μg/ml.
ELISPOT ASSAYS
Wells of 96-well plates (MultiScreen-IP ﬁlter Plate, PVDF, Mil-
lipore) were coated with 1μg of pdmHA overnight at 4˚C, and
blocked with fetal calf serum. Fifty microliters of culture medium
containing the cell populations to be assayed, or as a control
medium alone, were added to each well, and the plate was incu-
bated for overnight at 37˚C to allow secretion of antibodies.
AntibodiesagainstpdmHAwerecapturedintheimmediatevicin-
ity of the secreting cell. The spots of anti-HA antibodies that had
been secreted by individual PB were visualized by incubation with
a mixture of goat antibodies against the human Kappa or Lambda
chains conjugated with alkaline phosphatase (SouthernBiotech),
developed using BCIP/NBT as a substrate.
COMPETITION ELISA WITH C179 OR I5-24
The indicated competing antibodies were pre-incubated on the
pdmH1N1 vaccine-coated plate for 1h before addition of C179
or biotinylated I5-24 at a ﬁnal concentration of 0.2μg/ml. The
binding of C179 or biotinylated I5-24 was assayed respectively
by goat anti-mouse immunoglobulins or streptavidin conjugated
with alkaline phosphatase.
LOW pH-TREATMENT OF HA BOUND TO ELISA PLATES
Pandemic H1N1 vaccine (2μg/ml), or H9 HA (2μg/ml; BEI
Resources) was coated to ELISA plates overnight and wells were
treated by adding fusion buffer (10mM HEPES,10mM MES,pH
5), or as a control PBS at pH 7.4, and incubated for 1h at 37˚C.
Plates were then washed with PBS and the indicated mAbs were
titrated and assayed in the normal way.
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MICRONEUTRALIZATION OF pdmH1N1 ASSAY
The assay was performed ﬁrst following the WHO Manual on
AnimalInﬂuenzaDiagnosisandSurveillance(www.wpro.who.int/
internet/resources.ashx/CSR/Publications/manual+on+animal+
ai+diagnosis+and+surveillance.pdf). Brieﬂy, the monoclonal
antibody was subjected to twofold serial dilutions in a microtiter
plate beginning at 1:2 and an equal volume of pdmH1N1 virus
containing 100 TCID50 were added to each dilution and incu-
bated for 2h at 37˚C. The mixtures were added to respective
wells of a microtiter plate containing monolayers of MDCK cells
in serum-free Megavir medium containing TCPK-treated trypsin
andincubatedfor3hafterwhichthemediumwasreplacedbyfresh
Megavir medium containing TCPK-treated trypsin. The mono-
layers were monitored on days 3, 4, and 5 for the development
of cytopathic effect (CPE). The reciprocal of the highest dilution
of the antibody that inhibited the development of viral CPE was
designated as the titer. A modiﬁed form of the assay consisted of
eliminatingthestepof omittingtheremovalof thevirus-antibody
mixtures after 3h of incubation and allowing the mAb and the
virus to remain in the medium for the duration of the assay.
BINDING TO CELL-EXPRESSED H5 HA
Recombinant adenoviruses expressing inﬂuenza A HA (AdHA)
from A/Hong Kong/156/97 (H5N1; Hoelscher et al., 2008)w e r e
provided by Dr. Suryaprakash Sambhara (Centers for Disease
ControlandPrevention,Atlanta,GA,USA).TheAdHAproprotein
convertase (AdHA-PC) containing the HA multi-basic cleavage
site was utilized. The Adenovirus empty (AdEmpty) was used
as a negative control (Viraquest Inc.). To promote HA stability,
NH4Cl (10mM) was added to the culture medium during AdHA
infection. Monolayers of A549 cells in 96-well plates were infected
with AdHA at a MOI of 500 and incubated for 40h prior to ﬁx-
ation with 4% formaldehyde. Then, cells were incubated with the
indicated concentrations of mAb and treated with FITC-labeled
anti-human immunoglobulin antibodies. Nuclei were counter-
stainedwithHoechst.Imageswererecordedandanalyzed/counted
using the Cellomics instrument (Thermo Scientiﬁc). Data shown
are the average of duplicate measurements from a representative
experiment.
ASSAY FOR INHIBITION OF HA-MEDIATED FUSION
A549 cells were seeded and infected with AdHA as described in
themethodforthebindingassay.At40hpost-infection,cellswere
washed with PBS, and incubated with the indicated antibodies
(20μg/ml) for 30min at 37˚C. Then, cells were washed again and
treated with fusion buffer (10mM HEPES, 10mM MES, pH 5)
for 5min at room temperature. Media was replaced with nor-
mal cell culture media and cells were incubated at 37˚C for a 5-h
period to allow for syncytia formation. To monitor syncytia for-
mation,cellswerelabeledwith10μMCellTrackerGreenCMFDA
(Molecular Probes) for 30min at 37˚C, followed by further incu-
bation for 30min in fresh media before samples were ﬁxed with
4% formaldehyde. Nuclei were counterstained with Hoechst dye
(1μg/ml). Images were analyzed using the Cellomics system.
H5N1 PLAQUE REDUCTION ASSAY
Approximately 250 plaque forming units (PFU) of inﬂuenza
viruses A/Goose/Ger/R1400/07 (H5N1) and A/Ck/Ger/R28/03
(H7N7) were incubated in triplicate with the mAbs at twice the
indicated ﬁnal concentrations at 37˚C for 1h at a ﬁnal volume
of 80μl. 40μl of the virus-antibody mixtures were transferred
onto MDCK cell monolayers in 96-well plates and incubated
for 1h at 37˚C. Then the cells were overlaid with 40μl of 1.5%
carboxy-methyl cellulose. 30h later, plaques were visualized by
immunostaining using a mouse monoclonal anti-NP antibody
(F26NP9-2-1). Plaques were counted and % neutralization was
calculated by setting the infection without mAb as 0% neutral-
ization. Data shown are the mean of triplicate measurements
with SD.
THERAPEUTIC AND PROPHYLACTIC TESTING OF ANTIBODIES AGAINST
FATAL PDMH1N1 AND H5N1 PNEUMONIA IN MICE
The human clinical isolate of pandemic H1N1 inﬂuenza,
A/Halifax/210/2009 or the H5N1 vaccine strain, A/Hong
Kong/213/2003 on the PR8/34 backbone were used to induce
fatal viral pneumonia in CD-1 mice or BALB/c mice respectively.
Groups of 5 CD-1 or BALB/c mice (19–21Gm, females) were
infected under halothane anesthesia (3.5% in O2) with 50μlo f
2×105 pfu of either H5N1 or pmdH1N1 virus in PBS. Mice were
either treated with an intraperitoneal injection of 0.5ml of puri-
ﬁedmonoclonalantibodies1daybeforeor1–2daysafterinfection
to monitor protective or therapeutic effects. Controls were treated
with only PBS. Survival and weight loss was monitored for 12–
14daystoassesstheeffectsagainstfatalpandemicH1N1orH5N1
infections in mice. Similarly, mice were either treated with an
intraperitoneal injection of 400μl of human plasma 1day before
or 400μl of human plasma for each of 3, 2, or 1days before
infection with H5N1 to monitor protective effects.
ETHICS STATEMENT
Animal studies were performed under the supervision of a vet-
erinarian (DVM) and carried out in compliance with the guide-
lines of the Canadian Council on Animal Care (CCAC) as out-
lined in the Care and Use of Experimental Animals, Vol. 1, 2nd
Edn. (1993). The animal care protocol was approved by the
University of Ottawa Animal Care Committee (Protocol Num-
ber: BMI-85) and all efforts were made to minimize suffering
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resulted in greater than 30% body weight loss plus respiratory
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